FindTrial
Sign In

efficacy of habbul aas in the management of heavy flow during menses

Efficacy of Habbul Aas (Myrtus communis) in Kasrate Tams - A single blind randomized standard control study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/09/009937
Enrollment
40
Registered
2017-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Menorrhagia

Interventions

Intervention1: Myrtus communis (Habbul aas): 3 capsules 750 mg TID after meals for 5 days during menses starting form day one for two consecutive cycles Control Intervention1: Tranexamic acid: Tranexa

Sponsors

Luqman Unani Medical College
Lead Sponsor
Mariyam Roqaiya
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age:18 to 35 yrs 2 Women with regular menstrual cycle 3 Patient of menorrhagia assessed by PBAC

Exclusion criteria

Exclusion criteria: 1.Pregnancy and lactation. 2.Patient with irregular and intermenstrual bleeding. 3.Severe anaemia. 4.Patient with H/o Hypertension, DM, endocrine disorders •Patient with recent H/o Dengue and Chickenguniya •H/o Bleeding Disorder

Design outcomes

Primary

MeasureTime frame
Change in PBAC scoreTimepoint: two months—

Secondary

MeasureTime frame
1.Change in Hb% 2.Change in Quality of life (SF-36 score) Timepoint: two months—

Countries

India

Contacts

Public ContactMariyam Roqaiya

Luqman Unani Medical College

dr.mroqaiya@gmail.com9632560839

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 17, 2026